BenevolentAI interims highlight progress and potential of AI-driven drug discovery
BenevolentAI (OTC:BAIVF), the AI-driven biopharma drug discovery working with the likes of AstraZeneca and Merck, today announced its interim results…
60,750€
0,41%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Fortune 500 giant will open bioanalytical laboratory in Gothenburg
Thermo Fisher Scientific will expand its bioanalytical presence in Europe and has chosen Gothenburg, Sweden, as a base for its…
FASENRA EGPA US FDA APPROVAL
18 September 2024
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed…
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
The FDA okays AstraZenecas Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for…
AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
…
Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind…
Astrazeneca Aktie: Enttäuschende Studienergebnisse belasten Kurs
Die Astrazeneca-Aktie gerät unter Druck, nachdem die Deutsche Bank Research ihre Einschätzung von "Halten" auf "Verkaufen" herabgestuft und das Kursziel…
AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the…
AstraZeneca: Upgrade
Wien (www.aktiencheck.de) - Rating-Update:
Hans Engel, Analyst von Erste Group Research, stuft die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455,…
DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf Sell
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Astrazeneca von "Hold" auf "Sell" abgestuft und das Kursziel von 11000 auf…